Published in Neuropsychopharmacology on January 02, 2008
The molecular neurobiology of depression. Nature (2008) 6.51
The neurobiology of anhedonia and other reward-related deficits. Trends Neurosci (2011) 2.36
Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol (2009) 2.33
Ketamine for depression: where do we go from here? Biol Psychiatry (2012) 2.21
A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry (2009) 2.15
Anterior cingulate desynchronization and functional connectivity with the amygdala during a working memory task predict rapid antidepressant response to ketamine. Neuropsychopharmacology (2010) 1.65
Neurobiological mechanisms in major depressive disorder. CMAJ (2009) 1.49
Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov (2010) 1.47
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS. Front Mol Neurosci (2011) 1.47
Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: relationship to treatment resistance in major depressive disorder. Biol Psychiatry (2008) 1.42
Ketamine for treatment-resistant unipolar depression: current evidence. CNS Drugs (2012) 1.38
Target identification for CNS diseases by transcriptional profiling. Neuropsychopharmacology (2008) 1.32
Animal models of depression: molecular perspectives. Curr Top Behav Neurosci (2011) 1.31
Is there anything really novel on the antidepressant horizon? Curr Psychiatry Rep (2012) 1.17
Antidepressant-like effects of low ketamine dose is associated with increased hippocampal AMPA/NMDA receptor density ratio in female Wistar-Kyoto rats. Neuroscience (2012) 1.14
A genome-wide association study of neuroticism in a population-based sample. PLoS One (2010) 1.09
From synapse to nucleus: novel targets for treating depression. Neuropharmacology (2009) 1.06
Sigma receptors: potential targets for a new class of antidepressant drug. Pharmacol Ther (2010) 1.05
Mapping anhedonia onto reinforcement learning: a behavioural meta-analysis. Biol Mood Anxiety Disord (2013) 1.02
Cell atrophy and loss in depression: reversal by antidepressant treatment. Curr Opin Cell Biol (2011) 1.01
Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectr (2013) 0.99
Use of insulin sensitizers for the treatment of major depressive disorder: a pilot study of pioglitazone for major depression accompanied by abdominal obesity. J Affect Disord (2011) 0.98
The association of interoceptive awareness and alexithymia with neurotransmitter concentrations in insula and anterior cingulate. Soc Cogn Affect Neurosci (2013) 0.97
Neurobiological alterations induced by exercise and their impact on depressive disorders [corrected]. Clin Pract Epidemiol Ment Health (2010) 0.94
Fetal alcohol spectrum disorders and abnormal neuronal plasticity. Neuroscientist (2011) 0.92
The neurobiology of depression--revisiting the serotonin hypothesis. I. Cellular and molecular mechanisms. Philos Trans R Soc Lond B Biol Sci (2012) 0.91
Effects of nicotine on depressive-like behavior and hippocampal volume of female WKY rats. Prog Neuropsychopharmacol Biol Psychiatry (2009) 0.89
Review: magnetic resonance spectroscopy studies of pediatric major depressive disorder. Depress Res Treat (2010) 0.89
Molecular pharmacology in a simple model system: implicating MAP kinase and phosphoinositide signalling in bipolar disorder. Semin Cell Dev Biol (2010) 0.87
Antidepressant effects of resveratrol in an animal model of depression. Behav Brain Res (2014) 0.87
Impact of adolescent GluA1 AMPA receptor ablation in forebrain excitatory neurons on behavioural correlates of mood disorders. Eur Arch Psychiatry Clin Neurosci (2014) 0.86
PI3K/Akt signaling pathway in the basolateral amygdala mediates the rapid antidepressant-like effects of trefoil factor 3. Neuropsychopharmacology (2012) 0.85
A selective neurokinin-1 receptor antagonist in chronic PTSD: a randomized, double-blind, placebo-controlled, proof-of-concept trial. Eur Neuropsychopharmacol (2010) 0.84
Design and fabrication of low-cost 1536-chamber microfluidic microarrays for mood-disorders-related serological studies. Sensors (Basel) (2013) 0.81
Somatic drugs for psychiatric diseases: aspirin or simvastatin for depression? Curr Neuropharmacol (2012) 0.81
Sweet success, bitter defeat: a taste phenotype predicts social status in selectively bred rats. PLoS One (2012) 0.80
Chronic treatment with AMPA receptor potentiator Org 26576 increases neuronal cell proliferation and survival in adult rodent hippocampus. Psychopharmacology (Berl) (2009) 0.80
Molecular imaging as a guide for the treatment of central nervous system disorders. Dialogues Clin Neurosci (2013) 0.79
NIMH initiatives to facilitate collaborations among industry, academia, and government for the discovery and clinical testing of novel models and drugs for psychiatric disorders. Neuropsychopharmacology (2008) 0.78
Drug development in pediatric psychiatry: current status, future trends. Child Adolesc Psychiatry Ment Health (2012) 0.77
Neuronal correlates of depression. Cell Mol Life Sci (2015) 0.77
Reproductive Neuroendocrine Pathways of Social Behavior. Front Endocrinol (Lausanne) (2016) 0.77
Functional neuroimaging in geriatric depression. Psychiatr Clin North Am (2011) 0.77
Neurotransmitter Systems in a Mild Blast Traumatic Brain Injury Model: Catecholamines and Serotonin. J Neurotrauma (2015) 0.76
Positron emission tomography molecular imaging in late-life depression. J Geriatr Psychiatry Neurol (2014) 0.76
Antidepressant effect of geranylgeranylacetone in a chronic mild stress model of depression and its possible mechanism. Exp Ther Med (2012) 0.75
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry (2006) 11.84
Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry (2007) 6.59
Defining clinical phenotypes of juvenile mania. Am J Psychiatry (2003) 5.49
Discovering endophenotypes for major depression. Neuropsychopharmacology (2004) 4.90
A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry (2010) 4.85
Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry (2013) 4.84
Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry (2005) 4.81
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov (2008) 4.46
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry (2010) 4.00
Psychobiology and molecular genetics of resilience. Nat Rev Neurosci (2009) 3.71
Abnormal attention modulation of fear circuit function in pediatric generalized anxiety disorder. Arch Gen Psychiatry (2007) 3.10
The psychobiology of depression and resilience to stress: implications for prevention and treatment. Annu Rev Clin Psychol (2005) 3.09
Publication bias and the efficacy of antidepressants. Am J Psychiatry (2009) 3.05
Childhood trauma associated with smaller hippocampal volume in women with major depression. Am J Psychiatry (2002) 3.05
Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry (2009) 3.04
Adolescent immaturity in attention-related brain engagement to emotional facial expressions. Neuroimage (2003) 2.98
Ventrolateral prefrontal cortex activation and attentional bias in response to angry faces in adolescents with generalized anxiety disorder. Am J Psychiatry (2006) 2.90
Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry (2012) 2.69
Reduced volume of orbitofrontal cortex in major depression. Biol Psychiatry (2002) 2.53
MRI and PET study of deficits in hippocampal structure and function in women with childhood sexual abuse and posttraumatic stress disorder. Am J Psychiatry (2003) 2.51
A functional magnetic resonance imaging study of bipolar disorder: state- and trait-related dysfunction in ventral prefrontal cortices. Arch Gen Psychiatry (2003) 2.36
Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol (2009) 2.33
The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci (2003) 2.28
Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Arch Gen Psychiatry (2007) 2.25
VNS therapy in treatment-resistant depression: clinical evidence and putative neurobiological mechanisms. Neuropsychopharmacology (2006) 2.24
Ketamine for depression: where do we go from here? Biol Psychiatry (2012) 2.21
Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology (2012) 2.17
Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J Neurosci (2004) 2.17
Long-term treatment with paroxetine increases verbal declarative memory and hippocampal volume in posttraumatic stress disorder. Biol Psychiatry (2003) 2.16
Amygdala and hippocampal volumes in adolescents and adults with bipolar disorder. Arch Gen Psychiatry (2003) 2.15
Neurobiology of resilience. Nat Neurosci (2012) 2.13
Toward constructing an endophenotype strategy for bipolar disorders. Biol Psychiatry (2006) 2.09
Differential effects of 5-HTTLPR genotypes on the behavioral and neural responses to tryptophan depletion in patients with major depression and controls. Arch Gen Psychiatry (2006) 2.09
Attention bias to threat in maltreated children: implications for vulnerability to stress-related psychopathology. Am J Psychiatry (2005) 2.08
Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry (2008) 2.05
Life stress, genes, and depression: multiple pathways lead to increased risk and new opportunities for intervention. Sci STKE (2004) 2.04
Positron emission tomographic imaging of neural correlates of a fear acquisition and extinction paradigm in women with childhood sexual-abuse-related post-traumatic stress disorder. Psychol Med (2005) 1.99
Response to emotional expressions in generalized social phobia and generalized anxiety disorder: evidence for separate disorders. Am J Psychiatry (2008) 1.99
Trauma exposure, posttraumatic stress disorder and depression in an African-American primary care population. J Natl Med Assoc (2006) 1.95
The neurobiology of the switch process in bipolar disorder: a review. J Clin Psychiatry (2010) 1.94
Neural and behavioral responses to tryptophan depletion in unmedicated patients with remitted major depressive disorder and controls. Arch Gen Psychiatry (2004) 1.92
Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology (2005) 1.90
Trauma, resilience, and recovery in a high-risk African-American population. Am J Psychiatry (2008) 1.89
Neural correlates of the classic color and emotional stroop in women with abuse-related posttraumatic stress disorder. Biol Psychiatry (2004) 1.85
A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry (2006) 1.83
AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol (2004) 1.79
Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology (2008) 1.79
Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord (2007) 1.74
Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry (2003) 1.71
An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry (2004) 1.71
Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry (2008) 1.71
Hippocampal volume, memory, and cortisol status in major depressive disorder: effects of treatment. Biol Psychiatry (2004) 1.70
Frontostriatal abnormalities in adolescents with bipolar disorder: preliminary observations from functional MRI. Am J Psychiatry (2003) 1.70
Increased amygdala activity during successful memory encoding in adolescent major depressive disorder: An FMRI study. Biol Psychiatry (2006) 1.68
Regional brain metabolic correlates of alpha-methylparatyrosine-induced depressive symptoms: implications for the neural circuitry of depression. JAMA (2003) 1.67
An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry (2005) 1.65
Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry (2006) 1.65
An overview of posttraumatic stress disorder in African Americans. J Clin Psychol (2006) 1.65
The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology (2006) 1.64
Developing an agenda for translational studies of resilience and vulnerability following trauma exposure. Ann N Y Acad Sci (2006) 1.62
Enduring mental health morbidity and social function impairment in world trade center rescue, recovery, and cleanup workers: the psychological dimension of an environmental health disaster. Environ Health Perspect (2008) 1.62
The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord (2009) 1.62
Deficits in social cognition and response flexibility in pediatric bipolar disorder. Am J Psychiatry (2005) 1.62
Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci (2004) 1.61
Neural correlates of declarative memory for emotionally valenced words in women with posttraumatic stress disorder related to early childhood sexual abuse. Biol Psychiatry (2003) 1.61
Frontotemporal alterations in pediatric bipolar disorder: results of a voxel-based morphometry study. Arch Gen Psychiatry (2005) 1.57
Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry (2008) 1.57
An integrated approach to evaluate faculty members' research performance. Acad Med (2009) 1.56
Mood disorders and medical illness: a major public health problem. Biol Psychiatry (2003) 1.56
A case of sustained remission following an acute course of ketamine in treatment-resistant depression. J Clin Psychiatry (2011) 1.55
Effects of tryptophan depletion on serum levels of brain-derived neurotrophic factor in unmedicated patients with remitted depression and healthy subjects. Am J Psychiatry (2005) 1.55
The Wnt signaling pathway in bipolar disorder. Neuroscientist (2002) 1.53
Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J Clin Psychiatry (2009) 1.51
Tryptophan depletion and emotional processing in healthy volunteers at high risk for depression. Biol Psychiatry (2011) 1.51
Reduced hippocampal volume in unmedicated, remitted patients with major depression versus control subjects. Biol Psychiatry (2005) 1.51
Neurobiological mechanisms in major depressive disorder. CMAJ (2009) 1.49
The science of resilience: implications for the prevention and treatment of depression. Science (2012) 1.48
Mood-congruent bias in affective go/no-go performance of unmedicated patients with major depressive disorder. Am J Psychiatry (2005) 1.48
Age, rapid-cycling, and pharmacotherapy effects on ventral prefrontal cortex in bipolar disorder: a cross-sectional study. Biol Psychiatry (2006) 1.47
A developmental examination of gender differences in brain engagement during evaluation of threat. Biol Psychiatry (2004) 1.45
Modulation of synaptic plasticity by antimanic agents: the role of AMPA glutamate receptor subunit 1 synaptic expression. J Neurosci (2004) 1.45
Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists. CNS Drugs (2010) 1.43
Neural response to catecholamine depletion in unmedicated subjects with major depressive disorder in remission and healthy subjects. Arch Gen Psychiatry (2008) 1.42
Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: relationship to treatment resistance in major depressive disorder. Biol Psychiatry (2008) 1.42
Beta-catenin overexpression in the mouse brain phenocopies lithium-sensitive behaviors. Neuropsychopharmacology (2007) 1.42
Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology (2007) 1.41
In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology (2004) 1.41
Investigation of post-transcriptional gene regulatory networks associated with autism spectrum disorders by microRNA expression profiling of lymphoblastoid cell lines. Genome Med (2010) 1.41
Brain derived neurotrophic factor (BDNF) gene variants and Alzheimer's disease, affective disorders, posttraumatic stress disorder, schizophrenia, and substance dependence. Am J Med Genet B Neuropsychiatr Genet (2006) 1.41
Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder. Biol Psychiatry (2007) 1.40
Priority actions to improve the care of persons with co-occurring substance abuse and other mental disorders: a call to action. Biol Psychiatry (2004) 1.39
Molecular effects of lithium. Mol Interv (2004) 1.39
Life-threatening danger and suppression of attention bias to threat. Am J Psychiatry (2010) 1.39
A functional magnetic resonance imaging study of deliberate emotion regulation in resilience and posttraumatic stress disorder. Biol Psychiatry (2009) 1.38